• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background

    Malignant Lymphoma Companies

    ID: MRFR/Pharma/1329-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Malignant lymphomas are a group of cancers that originate in the lymphatic system, primarily involving lymphocytes (a type of white blood cell). The most common types of malignant lymphomas are Hodgkin lymphoma and non-Hodgkin lymphoma. Companies involved in the field of malignant lymphoma may contribute to various aspects, including research, development of diagnostic tools, and production of therapeutic interventions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Malignant Lymphoma Market Research Report- Global Forecast To 2030 Infographic
    Summary Table of Contents Segmentation Download PDF

    Top Industry Leaders in the Malignant Lymphoma Market

    Malignant Lymphoma Key CompaniesLatest Malignant Lymphoma Companies Update



    • June 2023:  Part C of a phase 2 single-arm trial evaluating the antibody-drug conjugate ADCETRIS® (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients with early-stage classical Hodgkin lymphoma (cHL) yielded updated efficacy and safety results, as reported by Seagen Inc. ADCETRIS + AVD chemotherapy (Adriamycin, vinblastine, dacarbazine) is the only targeted therapy-inclusive regimen with a statistically significant overall survival benefit at 6-years of follow-up, reducing the risk of death for these patients by 41%. It is the standard of care in the United States for advanced-stage cHL according to national treatment guidelines. On behalf of Takeda, ADCETRIS has been granted approval for five indications in Europe and seven indications in the United States.




    • June 2023: A clinical-stage biopharmaceutical company, Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today disclosed new data for CPI-818, the Company's ITK inhibitor, showcasing its potential as an immunotherapy agent for a range of solid and hematological malignancies via an innovative mechanism of action. The data encompass revised interim findings from the CPI-818 Phase 1/1b clinical trial, which further illustrate the potential of absolute lymphocyte count (ALC) as a biomarker and ITK inhibition in T cell lymphoma (TCL). The data from CPI-818, which was presented at the ICML meeting, illustrates the potential of ITK inhibition as an innovative immunotherapeutic mechanism of action in the treatment of cancer. The preclinical and clinical data collectively support a comprehensive and consistent rationale grounded in the biology and mechanism of immune enhancement that selectively inhibits ITK.


    List of Malignant Lymphoma Key companies in the market


    • Abbott Laboratories




    • Actelion Pharmaceuticals




    • Allos Therapeutics




    • Bristol-Myers Squibb Company




    • Celgene Corporation




    • Genmab




    • Inovio Pharmaceuticals




    • Johnson & Johnson




    • Onyx Pharmaceuticals




    • Seattle Genetics




    • ABIOGEN PHARMA S.P.A